Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 October 2021 | Story Lunga Luthuli and Vicky Simpson | Photo Supplied
Anton Engelbrecht _ Farmovs researcher
Anton Engelbrecht, FARMOVS Bioanalysis Specialist.

“At FARMOVS, we have the opportunity to work with the world’s top pharmaceutical companies, where we form part of the evaluation of labelled and/or conjugated antigens and antibodies that are developed for accurate quantification of endogenous and pharmaceutical compounds. Alternatively, commercially available kits and reagents are also used for the same purpose if the sponsor cannot supply the customised antigens/antibodies. The developed assay methods are put through a rigorous validation assessment to confirm the selectivity, sensitivity, and robustness of the assay,” says Anton Engelbrecht, FARMOVS Bioanalysis Specialist. 

FARMOVS, affiliated to the University of the Free State and operating from the Bloemfontein Campus, is a leading clinical research organisation (CRO) with a unique advantage. As the only on-site ISO15189-accredited and GLP-certified pharmacokinetic laboratory on the African continent, with numerous successful inspections by leading international regulators, it offers the highest quality bioanalytical services in a variety of biological matrices for the development of pharmaceutical products.

Engelbrecht says: “The team of bioanalytical experts thrives on the excitement generated by new discoveries that lead to better treatment of a variety of physiological diseases.”

Advanced technology backed by 47 years of bioanalytical experience

The clinical research organisation prides itself on advanced technology, backed by 47 years of bioanalytical experience. It has developed more than 580 validated analytical methods that adhere to the International Council for Harmonisation and the US Food and Drug Administration (FDA) guidelines. FARMOVS’ analytical methods have been used in more than 3 000 pre-clinical and clinical trials, contributing to the manufacturing of pharmaceutical drugs that are now used by households across the globe.

At FARMOVS, Engelbrecht says, it is a “world filled with novel methods of analysis and subsequent technological integration that expands the horizons of clinical research forming an important part of the discovery and production of new life-saving medicines that is constantly improving the quality of life of people all over the world”.

Engelbrecht says: “New technology and innovation should be the building blocks of any laboratory, and among these are the three fastest sample production members of our Immunochemistry Laboratory team – the STARLet pipettors.”

“We chose the Microlab® STARLet apparatus by Hamilton, because of its ability to perform sample analysis in large quantities at a greater speed by means of robotic pipetting and robotic automated microplate reading, which is a semi-automated process.”

He shared his excitement about improvements in the field of immunoassay development for the purposes of pharmaceutical analysis. This involves the preparation of unique immunoanalytical reagents, analysis of new categories of compounds, methodology, and instrumentation. The most important examples in this field are the continuous development of bead-based immunoassays.

Staying competitive in the industry

Immunoassay methods, such as radioimmunoassay (RIA) and enzyme immunoassay (EIA), among others, are also used at FARMOVS to analyse macromolecules for clients. “The RIA method is used for the determination of several pharmaceutically important compounds in biological fluids. RIA requires a sample containing the antigen of interest, a complementary antibody, and a radiolabelled version of the antigen. To increase the selectivity of an assay, all samples are pre-treated to eliminate high molecular weight endogenous matrix components, including anti-drug antibodies,” explains Engelbrecht.

Although FARMOVS has adequate technology to provide market-related results, the plan is to expand the team to include a multiplex platform that is a sensitive, fully automated immunoassay platform with multiplexing and custom assay capability. “This will pave the way to use an even more sensitive method to quantify biomarkers in the fields of oncology, neurology, cardiology, inflammation, and infectious disease. We aim to remain competitive in our industry, so naturally we must recruit the brightest and most evolved to join the team,” he says.

News Archive

New Rector and Chancellor inaugurated at UFS
2003-02-07

NEW RECTOR AND CHANCELLOR INAUGURATED AT UFS

 Newly inaugurated Rector and Vice-Chancellor of the University of the Free State, Prof Frederick Fourie, has recommitted the university to the service of the broader community, through the pursuit of academic excellence and contributing to building a non-racial, democratic and just South Africa.

To make this a reality Prof Fourie proposed a social contract or accord between university constituencies and the community to chart the way forward to establishing a university that can meet the challenges of a developing democracy.

Prof Fourie was speaking at his inauguration ceremony on the Bloemfontein campus, where the former Ambassador to the United States, Dr Franklin Sonn, was also inaugurated as Chancellor of the UFS.

The twin inauguration ceremony – the first in the history of the UFS - was attended by former President Nelson Mandela, Education Minister, Kader Asmal, Free State Premier Winki Direko, and the executive mayor of Mangaung, Mr Pappie Mokoena, who all endorsed the appointments as evidence of the transformation of the UFS.

According to Prof Fourie, the greatest contribution that any university could make to social and economic development in South Africa was by being an excellent university that encouraged critical inquiry, scientific knowledge as well as community service.

“So whilst we cherish and foster the continuity of the university as part of the ageold international tradition of universities, this University embraces its particular role in this country now, embraces the changes in the form and scope of its role in this crucial period of our history. We are committed to making a real difference to the new nation,” he said.

His vision for the UFS was “to be a university of excellence, equity and innovation – a leader in research, teaching, community service, adult learning, transformation, non-racialism, non-sexism, multi-culturality and multilingualism – a contributor to our country and our continent’s growth and development – a truly South African university”.

Prof Fourie said the recent incorporation of the Qwaqwa campus of the University of the North into the University of the Free State, which is the first such incorporation to take place, would contribute to broadening access for poor communities to higher education. Introducing an innovation to the inauguration ceremony, Prof Fourie and the UFS staff pledged to their commitment to excellence and justice, quality and equity. Fourie is the 13th Rector of the University of the Free State, succeeding Prof. Stef Coetzee, and Dr Sonn is the 6th Chancellor, succeeding Ms Winkie Direko, Premier of the Free State.

In his inaugural address, Dr Sonn said the significance of today’s ceremony was that the UFS - as a former institution of the Afrikaner – had chosen to walk the path of justice and not merely survival. “This university has seemingly liberated itself. It is inclusively South African.

He said the academic community must play its role of vigilance and not indifference”. Referring to the stature of former president Mandela in international affairs, Dr Sonn said: “We must bring the weight ot science and critical analysis and interpretation to bear in support of Madiba and other moral giants.”
 

 

Inauguration Speech by Prof. Frederick C.v.N. Fourie  (PDF format)

Inauguration Speech by Dr Franklin A. Sonn (PDF format)

Statement by the Minister of Education, Professor Kader Asmal (PDF format)

Speech by Prof. Viljoen (PDF format)

Speech by Executive Mayor Mokoena - Mangaung Local Municipality (PDF format)

 

 

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept